SSCRIPTURAclinical · decision · supportScriptura
Sign in
Patient sign inClinician sign in

Clinician reference, evidence review

BPC-157

Body Protection Compound 157

Cytoprotective peptide, research grade, not FDA approved

Reviewed by: Sabrina Runbeck, PA-C, MHS, MPH, Co-Founder, Scriptura Health. Physician assistant, public health master's, health sciences master's. Sabrina reviews the clinical layer of Scriptura Health, and she reviews every compound reference on this site.

Published: 2026-07-08. This page is an evidence review, not clinical instruction, and does not recommend dosing, cadence, routes, or prescribing decisions. Prescribing is the responsibility of a licensed clinician evaluating a specific patient.

Regulatory posture

BPC-157 is not approved by the FDA for any indication and has no marketing authorization in the United States. In 2023 the FDA placed BPC-157 in a category of substances that are difficult to compound and raised concerns about its safety and characterization, which limits lawful 503A and 503B compounding. It is not a controlled substance under the DEA, but it is prohibited in sport by the World Anti-Doping Agency.

Mechanism, plain English

BPC-157 is a lab made string of 15 amino acids (the building blocks of proteins) based on a protein found in stomach fluid. In animal studies it appears to help tissues heal by encouraging new blood vessels to grow (a process called angiogenesis) and by influencing growth signals in muscle, tendon, and gut tissue. How it works in humans is still poorly understood because almost all of the mechanism data come from animals.

Evidence landscape

The published human evidence for BPC-157 is very limited, and most of what exists comes from rodent studies. A 2025 systematic review in orthopaedic sports medicine found that nearly all supporting data are preclinical, with no adequately powered randomized controlled trials in people to confirm efficacy for tendon, muscle, or joint healing. A 2025 narrative review reached a similar conclusion and emphasized safety uncertainty, product quality concerns, and the absence of long-term human data. A small 2025 pilot study reported that intravenous BPC-157 was tolerated in a limited group of participants, but it was not designed to establish efficacy and involved few subjects. Taken together, the literature supports interest but does not support efficacy or safety conclusions in humans.

Primary PubMed citations

  1. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review , Vasireddi N et al, HSS Journal, 2025. PMID: 40756949
  2. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing , McGuire FP et al, Current Reviews in Musculoskeletal Medicine, 2025. PMID: 40789979
  3. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study , Lee E et al, Alternative Therapies in Health and Medicine, 2025. PMID: 40131143

Citations selected from the PubMed literature. Every URL was checked at publication time. Scriptura's daily PubMed scan surfaces new studies for each compound as they index. See the regulatory and literature layers on the demo.

Scope of this page

This is a plain English summary of the peer reviewed literature and current regulatory posture. It is not a substitute for a licensed clinician's judgment on a specific patient. It does not recommend dosing, cadence, or route. Where the literature is limited or preclinical, this page says so, so a prescriber can weigh marketing claims against what the trials actually show.

More clinician references

  • TB-500 , Regenerative peptide, research grade, not FDA approved
  • Semaglutide , GLP-1 receptor agonist, FDA approved
  • Tirzepatide , Dual GIP and GLP-1 receptor agonist, FDA approved
  • Retatrutide , Triple GIP, GLP-1, and glucagon receptor agonist, investigational, not FDA approved
  • CJC-1295 , Growth hormone releasing hormone analog, research grade, not FDA approved
  • Ipamorelin , Growth hormone secretagogue, research grade, not FDA approved
  • Sermorelin , Growth hormone releasing hormone analog, research grade, not currently FDA marketed
  • Tesamorelin , Growth hormone releasing hormone analog, FDA approved
  • Thymosin Alpha-1 , Immunomodulatory peptide, not FDA approved in the US, orphan drug status

Want the evidence layer for your practice.

A daily one page regulatory brief and a plain English PubMed literature delta, in your Drive every morning. No prescribing, no dispensing, no pharmacy routing. Just the evidence and regulatory read a prescriber wants before writing the next protocol.

Book a demoRequest access
BPC-157 clinician reference: evidence review and regulatory posture | Scriptura Health | Scriptura Health